Investor Presentation
122
Investor presentation First six months of 2022
Rest of World at a glance
Rest of World
Diabetes trend
Million
21%
DKK
billion
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
First half of 2022
Sales
(mDKK)
Growth²
300
Total GLP-13
3,526
92%
250
18%
80%
Long-acting insulin4
1,285
9%
Premix insulin5
1,292
3%
60
GLP-1
200
Fast-acting insulin
1,201
7%
31%1
60%
Insulin
Human insulin
1,321
-11%
150
286
40
40
1%1
Total insulin
5,099
1%
40%
Other Diabetes care?
279
15%
227
100
187
Diabetes care
8,904
25%
20
20
4%1
OAD
20%
Obesity care
886
29%
50
(SaxendaⓇ)
Diabetes & Obesity
9,790
25%
0
2021
0
0%
care
2030
2045
May
2017
May
2022
Rare disease8
2,667
7%
Population with diabetes
Diabetes growth rate
Total
12,457
21%
GLP-1 MS
-Insulin MS
OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: South & Central America, Southeast Asia
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of May 2022: Novo Nordisk 57%, Sanofi
24% and Eli Lilly 14%; Competitor GLP-1 value market shares, as of May 2022: Novo
Nordisk 62%, Eli Lilly 37% and AstraZeneca 1%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, May 2022 value
figures
2 At constant exchange rates; 3 Comprises Victoza®, OzempicⓇ and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ: 5 Comprises NovoMixⓇ and
RyzodegⓇ6 Comprises NovoRapidⓇ and Fiasp®;7 Comprises Novo NormⓇ and
needles; 8 Comprises primarily Esperoct®, Refixia ®, NovoSeven®, NovoEight®
and NorditropinⓇ
Source: Quarterly company announcementView entire presentation